

Publications 2010 onwards

1. Aitken Z, Walker K, Stegeman BH, Wark PA, Moss SM, McCormack VA, et al. Mammographic density and markers of socioeconomic status: a cross-sectional study. *BMC.Cancer* 2010;10:35.
2. Bennett RL, Evans AJ, Kutt E, Record C, Bobrow LG, Ellis IO, et al. Pathological and mammographic prognostic factors for screen detected cancers in a multi-centre randomised, controlled trial of mammographic screening in women from age 40 to 48 years. *Breast* 2011;20(6):525-8.
3. Bennett RL, Moss SM. Screening outcomes in women over age 70 who self-refer in the NHSBSP in England. *J Med Screen* 2011;18(2):91-5.
4. Bennett RL, Sellars SJ, Blanks RG, Moss SM. An observational study to evaluate the performance of units using two radiographers to read screening mammograms. *Clin Radiol* 2011.
5. Bennett RL, Sellars SJ, Moss SM. Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. *Br J Cancer* 2011;104(4):571-7.
6. Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de Koning H, et al. Lead-time in the European Randomised Study of Screening for Prostate Cancer. *Eur J Cancer* 2010;46(17):3102-8.
7. Harnden P, Coleman D, Moss S, Kodikara S, Griffin NR, Melia J. Evaluation of the use of digital images for a national prostate core external quality assurance scheme. *Histopathology* 2011;59(4):703-9.
8. Kelly R, Walker P, Kitchener H, Moss S. Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities. *BJOG* 2011.
9. Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. *Br J Cancer* 2011;105(7):983-8.
10. Kilpelainen TP, Tammela TL, Roobol M, Hugosson J, Ciatto S, Nelen V, et al. False-positive screening results in the European randomized study of screening for prostate cancer. *Eur J Cancer* 2011;47(18):2698-705.
11. Kingston N, Thomas I, Johns L, Moss S. Assessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial. *Cancer Epidemiol.Biomarkers Prev.* 2010;19(4):1132-36.
12. Kitchener HC, Blanks R, Dunn G, Gunn L, Desai M, Albrow R, et al. Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. *Lancet Oncol* 2011;12(1):56-64.
13. Lee TJ, Rutter MD, Blanks RG, Moss SM, Goddard AF, Chilton A, et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. *Gut* 2011.
14. Melia J, Coulson P, Moss S, Coleman D. Effects of a prostate awareness pilot on GP consultations and PSA requests. *Fam.Pract.* 2010;Feb 27(1):69-76.
15. Moss S. Screening women aged 40-49 years. *Prev Med* 2011;53(3):105-7.
16. Moss SM, Campbell C, Melia J, Coleman D, Smith S, Parker R, et al. Performance measures in three rounds of the English bowel cancer screening pilot. *Gut* 2012;61(1):101-7.
17. Scholefield JH, Moss SM, Mangham CM, Whyntes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. *Gut* 2011.

18. Wright KC, Harnden P, Moss S, Berney DM, Melia J. A practical application of analysing weighted kappa for panels of experts and EQA schemes in pathology. *J Clin Pathol* 2011;64(3):257-60.
19. Wright KC, Melia J, Moss S, Berney DM, Coleman D, Harnden P. Measuring interobserver variation in a pathology EQA scheme using weighted kappa for multiple readers. *J Clin Pathol* 2011;64(12):1128-31.
20. Kilpeläinen TP, Tammela TL, Roobol M, Hugosson J, Ciatto S, Nelen V, Moss S, Määttänen L, Auvinen A. False-positive screening results in the European randomized study of screening for prostate cancer. *Eur J Cancer*. 2011 Dec;47(18):2698-705
- 21: Moss S. Screening women aged 40-49 years. *Prev Med*. 2011 Sep 1;53(3):105-7.
- 22: Bennett RL, Evans AJ, Kutt E, Record C, Bobrow LG, Ellis IO, Hanby A, Moss SM. Pathological and mammographic prognostic factors for screen detected cancers in a multi-centre randomised, controlled trial of mammographic screening in women from age 40 to 48 years. *Breast*. 2011 Dec;20(6):525-8.
- 23: Kitchener HC, Blanks R, Dunn G, Gunn L, Desai M, Albrow R, Mather J, Rana DN, Cubie H, Moore C, Legood R, Gray A, Moss S. Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. *Lancet Oncol*. 2011 Jan;12(1):56-64.
- 24: Beral V, Alexander M, Duffy S, Ellis IO, Given-Wilson R, Holmberg L, Moss SM, Ramirez A, Reed MW, Rubin C, Whelehan P, Wilson R, Young KC. The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. *J Med Screen*. 2011;18(4):210-2
- 25: Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenber BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ECRSP Investigators. Prostate-cancer mortality at 11 years of follow-up. *N Engl J Med*. 2012 Mar 15;366(11):981-90.
- 26: Bennett RL, Sellars SJ, Blanks RG, Moss SM. An observational study to evaluate the performance of units using two radiographers to read screening mammograms. *Clin Radiol*. 2012 Feb;67(2):114-21.
- 27: Kelly RS, Walker P, Kitchener H, Moss SM. Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities. *BJOG*. 2012
- 28: Moss SM, Campbell C, Melia J, Coleman D, Smith S, Parker R, Ramsell P, Patnick J, Weller DP. Performance measures in three rounds of the English bowel cancer screening pilot. *Gut*. 2012 Jan;61(1):101-7
29. Scholefield JH, Moss SM, Mangham CM, Whyne DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. [Gut](#). 2012 Jul;61(7):1036-40
- 30.: Blanks RG, Moss SM. The calculation of targets for the cancer and adenoma detection rates for the NHS bowel screening programme. *J Med Screen*. 2012 Jun;19(2):72-6
- 31 Legood R, Sadique Z, Patnick J, Kitchener H, Kelly R, Moss S. Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study. *Br J Cancer*. 2012 Oct 4. doi: 10.1038/bjc.2012.435. [Epub ahead of print]

32. Moss S, Ancelle-Park R, Brenner H. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition - Evaluation and interpretation of screening outcomes. *Endoscopy*. 2012 Sep;44 Suppl 3:SE49-64.
33. Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, Massat N, Duffy S, Lynge E, Paci E; EUROSCREEN Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen*. 2012;19 Suppl 1:14-25.
34. Moss SM, Nyström L, Jonsson H, Paci E, Lynge E, Njor S, Broeders M; Euroscreen Working Group. The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. *J Med Screen*. 2012;19 Suppl 1:26-32.
35. Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E; Euroscreen Working Group. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. *J Med Screen*. 2012;19 Suppl 1:33-41.
36. Legood R, Smith M, Lew J, Walker R, Moss S, Kitchener H, Patnick J, Canfell K. Cost-effectiveness of HPV test of cure following treatment for Cervical Intraepithelial Neoplasia in England: Results from the NHS Sentinel Sites Study. *BMJ*. 2012 Oct 31;345:e7086.
37. Lee TJ, Blanks RG, Rees CJ, Wright KC, Nickerson C, Moss SM, Chilton A, Goddard AF, Patnick J, McNally RJ, Rutter MD. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England. *Endoscopy*. 2013 Jan;45(1):20-6.
38. Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P. Standardization of Gleason grading among 337 European pathologists. *Histopathology*. 2013 Jan;62(2):247-256.
39. European Colorectal Cancer Screening Guidelines Working Group. European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. *Endoscopy*. 2013 Jan;45(1):51-59.
40. Gunsoy NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40-49 in the United Kingdom. *Breast Cancer Res*. 2012 Nov 29;14(6):R152. [Epub ahead of print]